Novartis Brazil The government recently released the BrasilMaior plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry here in Brazil? I think compared to, say, 10 years ago, the new government has understood that the pharmaceutical, biotech,…
ITF-Labomed Labomed was bought by Italfarmaco in 2009, but aside from that, what have been the main milestones and achievements of Labomed since its creation in 1968? When I came to Labomed in 1997, I began a process of renewing the company’s product portfolio and changing the overall profile of Labomed.…
Eli Lilly Chile Lilly’s portfolio ranges from products for cardiovascular diseases to neurological conditions. How has your portfolio developed in Chile? What therapeutic areas is Lilly favoring in the Chilean context? Lilly Chile has a long commitment of bringing innovative pharmaceuticals to the country and the majority of our products are very specialized.…
Genzyme Chile Genzyme was first established in Chile in 2004 but only opened its sales office in 2008, what was the rationale for the opening of the office at this time considering that you had been present in neighbouring countries 10 years before? The Chilean market is a very difficult one. We…
Meizler Biopharma There is little publicly available information on your personal history and the founding of Meizler. Can you share that story for our readers? Everybody has a story – unless they’re second generation, of course! I am an architect by training. Before entering the pharmaceutical industry I owned an engineering and…
Zodiac Pharmaceuticals What would you recommend in terms of increasing the competitiveness and growth of the Brazilian pharmaceutical industry? The Brazilian pharmaceutical industry needs to improve its R&D capabilities. I personally think that the country can’t build a strong pharmaceutical industry based only on generics. Generics are an important part of the…
Genzyme de Colombia S.A. What is the role, significance, and importance of the Colombian market within the larger global strategy of Genzyme international? Colombia is a very important country because we have a market with a well developed, and in that way different, health system from other countries in the Andean region. Of course…
Novo Nordisk Brazil Diabetes affects an estimated 6 million Brazilians, a figure which is expected to double by 2025, in line with many other developing nations. Like many other “rich-country” diseases, there is a tendency for its sudden prevalence to result in less-than-adequate treatment profiles. What have you observed here in Brazil? The…
Nefarma When it comes to the pharmaceutical and healthcare industries in the Netherlands, the country has one of the highest generic penetration rates in Europe, it does not have a strong manufacturing presence, and the market has been described as very regulated. Given all of this, what do you believe is…
Ferring BV Netherlands 2010 was a very important year for Ferring as it marks the 60th anniversary of the company’s founding. Amongst the various commemorations this year and in hearing the collective experiences of your general manager counterparts, what do you consider the main factors behind Ferring’s success over time? Perhaps the most…
Novo Nordisk Italy Novo Nordisk is one of the very few pharmaceutical multinationals that has such a strong focus on one therapeutic area. Although the company is now diversifying, diabetes remains its leading cause. Could you give us a brief overview of the evolution of diabetes in your country compared to the other…
ANVISA 10 days ago, your Swedish counterpart Mats Larsson made a technical visit here at ANVISA and said he had a lot to learn. What is it about ANVISA that can be learned by some of the richest, most developed countries in the world? I think that there is something very…
See our Cookie Privacy Policy Here
